Reimagining Perinatal Care in Alabama Through Innovative Partnerships.

Prostate cancer (PCa) stands as the world's second most commoncancer accordingto global statistics, with North and South America, Europe, Australia, and the Caribbean as the regions with the highest incidence rates [, ]. The risk of this disease arisesfrom multiple factors, including age, family medical history, genetic factors, and eating patterns. The development of this condition has been linked to external factors, which include tobacco use, physical exercise, particular drugs, and workplace dangers [, ]. The worldwide numbers of new prostate cancer cases and deaths will rise to 2.3 million because of changing population demographics, which include increasing numbers of people and an aging population []. The main cancer type affecting men remains prostate cancer, but this disease tends to progress slowly, which results in good survival outcomes when detected at an initial stage []. The current methods for prostate cancer detection face difficulties in identifying prostate cancer at its earliest stages with high accuracy, which makes surveillance systems and early detection methods essential for achieving better treatment results. The high mortality from prostate cancer is largely due to patients being diagnosed at advanced stages, which makes treatment ineffective [, ]. The diagnostic tools for prostate cancer include prostate biopsies, PSA assays, digital rectal examinations, MRI, and general health screenings []. PSA screening has become widespread throughout the 21 century, which has proven essential for reducing the number of PCa cases []. The PSA test shows specific results about prostate gland health, but it does not provide information about prostate cancer. The PSA levels, which rise above normal ranges, do not provide sufficient diagnostic accuracy because they can result from non-cancerous conditions, such as BPH and prostatitis [, ]. The gold standard for PCa diagnosis is biopsy, but these procedures have two major drawbacks: they are invasive, and they produce false-negative test results []. Research has made progress in prostate cancer detection and treatment through the discovery of new molecular markers, the development of mpMRI and PSMA-PET scans as advanced imaging technologies [, ]. The medical community now supports MRI scans as the first diagnostic test, which should be performed before prostate biopsy procedures for patients who have high-risk conditions []. The rapid development of artificial intelligence (AI) and machine learning technologies requires an autonomous algorithm to detect prostate cancer at its earliest stages, as early detection enables better medical outcomes through early intervention.